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Introduction: The 2-[18F]-Fluorodeoxyglucose (FDG) positron 
emission tomography (PET/CT) has become an imaging tool for 
clinical assessment of tumor, node, metastasis in non–small-cell lung 
cancer (NSCLC). Primary tumor maximum standardized uptake 
value (SUV
max
) on 18F-FDG PET/CT before and after radiation ther-
apy (RT) has been studied as a potential prognostic factor for NSCLC 
patients receiving radiotherapy. However, the sample sizes of most 
studies were small, and the results of the prediction value of SUV
max
 
remained undetermined, which lead us to perform a meta-analysis to 
improve the precision in estimating its effect.
Methods: We performed a meta-analysis of published literature for 
primary tumor SUV
max
-based biomarkers of the outcome of NSCLC 
receiving radiotherapy. The required data for estimation of individ-
ual hazard ratios (HRs) to compare patients with a low and a high 
SUV
max
 were extracted from each publication. A combined HR was 
calculated by Stata statistical software (Version 11). All of the results 
were verified by two persons to ensure its accuracy.
Results: Thirteen studies were finally included into this meta-analy-
sis; data are available in 13 studies for pre-RT primary tumor SUV
max
 
and in five studies for post-RT. For overall survival, the combined 
HR estimate was 1.05 (95% confidence interval [CI], 1.02–1.08) 
and 1.32 (95% CI, 1.15–1.51) for pre-RT SUV
max
 and post-RT 
SUV
max
, respectively; 1.26 (95% CI, 1.05–1.52) and 2.01 (95% CI, 
1.16–3.46) for local control (LC). In stereotactic body radiotherapy 
(SBRT) group, HR for LC was 1.11 (95% CI, 1.06–1.18) and 2.19 
(95% CI, 1.34–3.60) for pre-SBRT SUV
max
 and post-SBRT SUV
max
, 
respectively.
Conclusion: Both pre-RT and post-RT primary tumor SUV
max
 can 
predict the outcome of patients with NSCLC treated with radio-
therapy. Patients with high levels of pre-RT SUV
max
 seemed to have 
poorer overall survival and LC.
Key Words: Primary tumor maximum standardized uptake value, 
Prognosis, Non–small-cell lung cancer, Meta-analysis, Radiotherapy.
(J Thorac Oncol. 2014;9: 834–842)
Lung cancer is the leading cause of cancer-related death worldwide.1 Non–small-cell lung cancer (NSCLC) 
accounts for 85% of all lung cancers. NSCLC is often treated 
with a combination of multiple types of therapies, includ-
ing radiation therapy (RT). The dose limitation and therefore 
therapeutic efficacy of RT have been addressed by recent 
progresses, including stereotactic body radiotherapy (SBRT) 
and image-guided and intensity-modulated radiotherapy.2 For 
inoperable patients with early stage NSCLC, SBRT presents 
as a new standard treatment. Despite these improvements, 
the 5-year survival rate is generally approximately 15%,3 
and somewhat higher at 17% to 47%4 in patients with early 
stage NSCLC.
Information about reliable prognostic factors for RT 
responses (and prognosis in general) is essential in identify-
ing subjects suitable for aggressive RT treatment. The most 
commonly used factor for predicting RT responses is the 
tumor-node-metastasis (TNM) stage.5 Weight loss,6 perfor-
mance status,6 and molecular markers7,8 were reported to pre-
dict the outcome and could be used to stratify patients for the 
most optimal strategy for RT but require further validation.9 
Morphologic changes as reflected by computed tomography 
(CT) have also been identified as prognostic factors, but tech-
nical issues remain (e.g., it is also difficult to differentiate 
residual tumor from necrosis or fibrosis).10,11
A variety of imaging methods has been devel-
oped to examine tumor metabolism.12–14 For example, 
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18F-fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET)/CT is becoming the standard practice for staging 
and is widely used in post-treatment evaluation of various 
types of cancer, including breast cancer, lymphoma, head 
and neck cancer, and NSCLC.15–18 For NSCLC, 18F-FDG 
PET/CT has been found useful for diagnosing, restag-
ing at recurrence,19 delineating radiotherapeutic targets,20 
and evaluating radiotherapeutic or chemotherapeutic 
effects.19–21 Maximum standardized uptake value (SUV
max
) 
derived from 18F-FDG PET/CT has been reported by 
some,22–24 but not all,25,26 to predict the responses to RT in 
patients with NSCLC.
In the current study, we systematically reviewed avail-
able information of all published studies of primary tumor 
SUV
max
 of NSCLC. Potential prognostic value of primary 
tumor SUV
max
 in predicting RT responses was examined using 
meta-analysis.
MATERIALS AND METHODS
Search Strategy and Eligible Criteria
The PubMed database was searched (updated on 
April 3, 2013) used the following terms: (non–small cell 
lung cancer OR NSCLC) AND (PET imaging tomography 
OR positron emission tomography OR PET OR 18F-FDG 
OR fluorodeoxyglucose) AND (prognostic OR survival 
OR prognostic factor OR outcome OR predict) AND 
(“radiotherapy”[Mesh] OR radiotherapy OR irradiation). 
References cited by the articles identified in the electronic 
search were also reviewed. Conference Abstracts were not 
included in the search because of a lack of meta-analysis. 
When the same patient population was reported in more 
than one article, only the most recent or complete report was 
included in the final analysis.
This meta-analysis was limited to the studies on prog-
nostic implications (for either overall survival [OS] or local 
control [LC]) of primary tumor SUV
max
, as examined using 
18F-FDG PET/CT, in NSCLC patients receiving RT. Case stud-
ies and review articles were not included. Studies using prog-
nostic indexes other than OS or LC were also not included.
Data Extraction
Information was independently extracted by two investi-
gators (FFN and CL), and it included authors, publication year, 
source of patients, sample size, main primary tumor SUV
max
 
characteristics, tumor stage, treatment strategy, and survival 
information (Table 1). OS was defined as the period from the 
date of enrollment to the date of death. LC was defined as the 
time between diagnosis and the first local-regional failure.
Study Quality Control
The Newcastle–Ottawa Quality Assessment Scale27 was 
used to assess the methodological quality of the meta-analysis; 
each study was reviewed by two independent reviewers (FFN 
and CL). A “star system” is used to obtain the score. Briefly, 
each study was judged on three broad perspectives: the selec-
tion of the study groups, the comparability of the groups, 
and the ascertainment of either the exposure or outcome of 
interest. The number of total stars was used to reflect the qual-
ity of the included studies. The evaluation was performed by 
two investigators independently (FFN and CL).
Statistical Analysis
Stata statistical software Version 11.0 software (Stata 
Corporation, College Station, TX) was used to perform this 
meta-analysis. For OS and LC, hazard ratios (HRs) with 95% 
confidence interval (95% CI) were calculated. The inter-
study heterogeneity was evaluated with the Cochrane’s Q 
test (α = 0.05) as well as I 2.28 A ﬁxed effects model (Mantel–
Haenszel method) was used to analyze the data as to whether 
there was no significant heterogeneity; otherwise, a random 
effects model was used according to the DerSimonian–Laird 
method.29 Publishing bias was tested with the Begg’s and 
Egger’s bias indicator test.
HR and 95% CI were directly extracted from the studies 
that used a multivariate survival analysis22,23,30–35 or univariate 
analysis.25,26,36,37 If the HR was not given explicitly,24 p value 
and total events were used to calculate the HR based on a 
method reported by Tierney et al.38 The final combination of 
HR was the effect value to show the prognostic significance.
A sensitivity analysis was performed by including only 
studies of the highest quality (with seven or more stars) or 
with similar cutoffs.
RESULTS
Study Identification and Quality
The literature search identified 234 relevant stud-
ies, among which 170 studies were eliminated from further 
analysis by the screening based on title/abstract review and 
supplemental author searches. The full texts of the remaining 
64 articles were retrieved. Careful review of the full text elimi-
nated 51 articles because of a lack of sufficient data (Fig. 1). 
The final analysis included 13 articles, and, according to the 
sequence of 18F-FDG PET/CT and RT performing, they were 
divided into two groups: pre-RT primary tumor SUV
max
 and 
post-RT primary tumor SUV
max
. Five of the 13 studies had 
available data for both pre-RT SUV
max
 and post-RT SUV
max
; 
the remaining eight studies only had pre-RT SUV
max
 data. The 
quality of the included studies is shown in Table 1. The quality 
score ranged from 6 to 8 with a median of 7.38; all 13 stud-
ies satisfied most of the items and reported all of the assay 
method and confounders. Assessment of outcome was the 
worst described item.
Characteristics of the Included Studies
The basic characteristics of the included studies are 
summarized in Table 1. Studies are listed twice if they pro-
vided survival data for both pre-RT and post-RT. All the stud-
ies were published during a period from 2005 to 2013. The 
sample size ranged from 46 to 132.
All 13 studies reported pre-RT SUV
max
. In the eight 
studies (657 patients) that reported OS, three claimed signifi-
cant positive predict value of OS for RT. In the seven studies 
(530 patients) that reported LC, three claimed predict effect 
of LC for RT.
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Post-RT SUV
max
 was described in five studies (all five 
also described Pre-RT SUV
max
). In the three studies (227 
patients) that reported OS, two claimed that primary tumor 
SUV
max
 could predict OS for RT. In the four studies (391 
patients) that reported LC, three claimed significant positive 
predict value on LC for RT.
Tumor stage and RT regimen were described in most 
studies (Table 1). In the analysis of pre-RT SUV
max
, seven 
studies (54.5% of the total patients) focused on patients with 
stage I tumor; all these patients were treated with SBRT, for 
a total dose of 40 to 70 Gy. In the six remaining studies, the 
tumor stage was variable: stage I to III (n = 3), stage III (n = 2), 
stage III to IV (n = 1), and not given (n = 1), and the patients 
received conventional radiotherapy (CRT) with a total dose of 
55 to 77 Gy. In post-RT primary tumor SUV
max
, two studies 
included patients with stage III tumor, whereas the remaining 
three reports focused on stage I tumor and SBRT.
In all 13 studies included in the meta-analysis, all 
patients had fasted for at least 6 hours before PET/CT scan-
ning and had a measured blood sugar level approximately 
130 to 2000 mg/dl at the time of injection. The threshold level 
was 150 mg/dl24–26,30,34 in five studies, 200 mg/dl in three,23,33,36 
130 mg/dl31 in one, 175 mg/dl22 in one, and not given in the 
other three publications.32,35,37 All the studies obtained emis-
sion and transmission scans 60 minutes after the injection 
of 18F-FDG; however, the dose of 18F-FDG varied across 
the studies: 5 MBq/kg in three studies,22,35,36 10 to 20 mCi in 
four,26,33,34,37 10 to 15 mCi in three,25,31,32 and 3,30 3.5,23 and 7.4 
MBq/kg32 in the remaining three studies, respectively. Primary 
tumor SUV
max
 was normalized by body weight in all studies to 
minimize the partial volume effect.
“High” primary tumor SUV
max
 correlated with the out-
come. The cutoff for primary tumor SUV
max
 ranged from 5 to 
15 and was chosen with varying methods across the studies: 
four using the median SUV
max
 of the study sample, four using 
receiver-operating characteristic curve analysis, one referring 
to the validation results from another article, and one deter-
mined by log-rank test, and not described in the remaining two 
articles. Optimal timing of 18F-FDG PET/CT after the treat-
ment also varied considerably: 12 weeks (n = 2), 10 weeks 
(n = 1), 8 to 24 weeks (n = 1), and not described in the remain-
ing one study.32
Meta-Analysis
The analysis was performed separately for pre-
RT SUV
max
 and post-RT SUV
max
. The OS and LC data of 
both groups were analyzed. Eight studies reported pre-RT 
SUV
max
 and OS25,30,32,33–37; seven reported pre-RT SUV
max
 and 
LC22,23,25,26,30–32; three reported post-RT SUV
max
 and OS25,32,36; 
and four studies reported post-RT SUV
max
 and LC.22,25,26,36 
Pooled HRs was then calculated for all groups.
Higher pre-RT SUV
max
 was correlated with shorter OS 
(pooled HR, 1.69; 95% CI, 1.82–2.42). The heterogeneity was 
significant (I 2 statistic = 99%, P
heterogeneity
 = 0.000). A forest plot 
attributed most of the heterogeneity to one study.32 Reanalyzing 
the data after exclusion of this article (I 2 statistic = 11.9%, 
P
heterogeneity
 = 0.339) using a fixed effects model reduced the HR 
(fixed model) to 1.05 (95% CI, 1.02–1.08) (Fig. 2A). Sensitivity 
analysis (by excluding studies with or below six stars) revealed 
a combined HR at 1.05 (95% CI, 1.02–1.09) without heteroge-
neity (I 2 = statistic 25.2%, P
heterogeneity
 = 0.245), indicating that 
the sensitivity is low and the result is more robust and credible. 
FIGURE 1.   Flow diagram of 
the literature search strategy and 
assessment of studies identified for 
meta-analysis.
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The pooled HR estimate for LC of the six studies using a ran-
dom-effects model (I 2 statistic = 77.8%, P
heterogeneity
 = 0.000) 
was 1.26 (95% CI, 1.05–1.52) (Fig. 2B). The combined HR 
was 1.24 (95% CI, 1.04–1.49) n a sensitivity analysis (I 2 = sta-
tistic 79.5%, P
heterogeneity
 = 0.0255).
Post-RT SUV
max
 also correlated with OS and LC. 
For OS, the pooled HR was 2.47 (95% CI, 0.58–13.03; I 2 
statistic = 99.3%, P
heterogeneity
 = 0.000). Excluding the same 
study excluded in the post-RT/OS association,32 the HR was 
reduced to 1.32 (95% CI, 1.15–1.51) with well homogeneity 
(I 2 statistic = 0.0%, P
heterogeneity
 = 0.670) (Fig. 2C). The pooled 
HR estimate using a random effects model for LC was 2.01 
(95% CI, 1.16–3.46) (Fig. 2D). Again, there was consider-
able heterogeneity (I 2 statistic = 70.6%, P
heterogeneity
 = 0.017). 
A sensitivity analysis was assessed after excluding studies 
with six stars33 and excessive cutoff value (cutoff = 14).25 The 
combined HR (HR, 2.19; 95% CI, 1.34–3.60 and HR, 2.32; 
95% CI, 1.47–3.68) indicates that the sensitivity is low and 
the result is robust and credible.
The studies were stratified into two groups: SBRT and 
CRT. In pre-SBRT primary tumor SUV
max
 group, the subjects 
were stage I patients, and high pre-SBRT SUV
max
 was not 
significantly associated with poor OS (HR, 1.10; 95% CI, 
0.91–1.31) with modest homogeneity across the four included 
studies (I 2 statistic = 49.3%, P
heterogeneity
 = 0.245) (Fig. 3A). 
High pre-SBRT SUV
max
 also correlated to unfavorable LC 
(HR, 1.28; 95% CI, 1.02–1.60). Eliminating heterogene-
ity (I 2 statistic = 63.4%, P
heterogeneity
 = 0.018) by excluding a 
study that included T1-4N0M0 tumors23 reduced the HR esti-
mate for LC to 1.11 (95% CI, 1.06–1.18; I 2 statistic = 28.3%, 
P
heterogeneity
 = 0.242) (Fig. 3B). The post-SBRT SUV
max
 corre-
lated to LC (HR, 2.19; 95% CI, 1.34–3.60; I 2 statistic = 37.1%, 
P
heterogeneity
 = 0.204) (Fig. 3C), with limited data that prevented 
analysis of OS. For CRT, both high pre-CRT and post-CRT 
SUV
max
 correlated to poor OS (Table 2).
Publication Bias
Publication bias was assessed by Begg’s and Egger’s 
test. Begg’s test did not find overt publication bias. Formal 
evaluation using Egger’s test also failed to identify signifi-
cant publication bias in the analysis of pre-RT SUV
max
 versus 
OS (p = 0.317), and post-RT SUV
max
 versus LC (p = 0.916). 
FIGURE 2.  The association between primary tumor SUVmax and OS and LC of NSCLC treated by radiotherapy. A, The pooled 
HR estimate for OS of pre-RT primary tumor SUVmax; B, The pooled HR estimate for LC of pre-RT primary tumor SUVmax; C, 
The pooled HR estimate for OS of post-RT primary tumor SUVmax; D, The pooled HR estimate for LC of post-RT primary tumor 
SUVmax.  (OS, overall survival; LC, local control; HR, hazard ratio; CI, confidence interval.)
839Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014 Primary Tumor Standardized Uptake Value
Similarly, there was no evidence for significant publication 
bias in pre-SBRT SUV
max
 versus OS (p = 0.107) and in pre-
CRT SUV
max
 versus OS (p = 0.139). The results with hetero-
geneity adjusted are listed in Table 2.
DISCUSSION
During the past decade, the role of 18F-FDG PET/CT 
has become increasingly important to the patients staging and 
the radiation treatment planning process in NSCLCs. It has 
FIGURE 3.  The association between primary 
tumor SUVmax and OS and LC of NSCLC treated 
by SBRT. A, The pooled HR estimate for OS of 
pre-SBRT primary tumor SUVmax; B, The pooled 
HR estimate for LC of pre-SBRT primary tumor 
SUVmax; C, The pooled HR estimate for LC of post-
SBRT primary tumor SUVmax.
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been widely reported that SUV
max
 of the primary tumor in the 
18F-FDG PET/CT analysis has potential prognostic use among 
differently staged and treated populations.22,37,39 For patients 
with resectable NSCLC, a meta-analysis of 13 studies showed 
that primary tumor SUV
max
 has significant prognostic value on 
patient survival.39 Some previous studies suggested an asso-
ciation of high SUV
max
 before RT with poor LC22 and OS,34 
but such findings were not replicated by others.30
The results of the correct study confirmed a significant 
correlation of high level of both pre-RT and post-RT SUV
max
 
with the increased risk of death and local recurrence. Stratified 
analysis (SBRT versus conventional radiation) also confirmed 
the prognostic value of primary tumor SUV
max
 regardless of 
the type of the treatment. These results are generally consistent 
with a previous study,24 and particularly so for stage I NSCLC 
patients treated with SBRT. Whether SUV
max
 is a prognostic 
factor of the outcome in NSCLC patients receiving RT regard-
less of stage and performance status requires further evaluation.
In the analysis of pre-RT versus OS, most of the het-
erogeneity could be attributed to one study performed in 46 
Chinese patients with stage III NSCLC.32 This heterogeneity 
may be explained by the different methods used to estimate 
the results and the different threshold used. For example, the 
method used by the excluded study32 to estimate the results 
was logistic regression model. The analysis of post-RT with 
OS also had significant heterogeneity (because of the same 
study). Excluding the prediction value of primary tumor 
SUV
max
 for OS turned into significant (HR, 1.32; 95% CI, 
1.15–1.51) from insignificant (HR, 2.47; 95% CI, 0.58–13.03) 
and demonstrated a poorer OS with high SUV
max
. It is note-
worthy, however, that only two studies with 181 patients were 
included in meta-analysis with acceptable heterogeneity. The 
results, therefore, must be validated by additional studies. 
Varying cutoff levels, different scanning equipment, and frac-
tionated dose schemes also contributed to the heterogeneity.
Patients in all studies, including the SBRT subgroup 
analysis, had stage I NSCLC. As a result, the association 
of high pre-SBRT SUV
max
 with unfavorable OS and LC is 
not clear in patients with more advanced NSCLC. Also, the 
prognostic value of post-SBRT SUV
max
 on OS could not be 
confirmed in this meta-analysis because of the insufficient 
available data. A similar situation seems to be true of CRT as 
well: analysis of all five CRT studies using a random-effects 
model failed to confirm an association between the pre-CRT 
or post-CRT SUV
max
 and OS/LC; but reducing heterogene-
ity by excluding the study from China32 revealed significant 
association.
In addition to the absolute value of pre-RT or post-RT 
SUV
max
, the change of duel time primary tumor SUV
max
 also 
correlated with patient outcome after RT. A study by Clarke 
et al.22 found significantly higher rate of distant failure in 
patients with a post-SBRT SUV
max
 of 2 or more and a reduc-
tion of less than 2.55. Another study25 also reported the greater 
decrease in primary tumor SUV
max
 that had the highest SUV
max
 
at diagnosis, the longer OS and disease-free survival for RT. 
The Satoh study30 also suggested that, in comparison with 
pre-SBRT SUV
max
, high retention index and reduced ratio of 
SUV
max
 had better prognostic value (HR, 47.546; p = 0.026). 
The value of the change in dual time points FDG-PET/CT as 
a prognostic factor for outcome in NSCLC patients receiving 
RT needs to be further studied, with attention to the method of 
calculating this change and the cutoff value.
TABLE 2.   Meta-Analysis after Correcting Heterogeneity
Group Studies (N) Q test p Value Model Selected HR (95% CI) p Value Egger’s Test p Value
ALL
  OS
   Pre-RT 7 0.339 Fixed 1.05 (1.02–1.08) 0.001 0.117
   Post-RT 2 0.670 Fixed 1.32 (1.15–1.51) 0.000 —
  LC
   Pre-RT 8 0.000 Random 1.26 (1.05–1.52) 0.012 0.017
   Post-RT 5 0.024 Random 2.01 (1.16–3.46) 0.012 0.002
SBRT
  OS
   Pre-SBRT 4 0.116 Fixed 1.10 (0.91–1.31) 0.326 0.107
  LC
   Pre-SBRT 4 0.242 Fixed 1.11 (1.06–1.18) 0.000 0.057
   Post-SBRT 3 0.204 Fixed 2.19 (1.34–3.60) 0.002 0.015
CRT
  OS
   Pre-CRT 3 0.709 Fixed 1.05 (1.02–1.08) 0.001 0.777
   Post-CRT 2 0.670 Fixed 1.32 (1.15–1.51) 0.000 —
  LC
   Pre-CRT 2 0.000 Random 2.44 (0.39–15.45) 0.343 —
   Post-CRT 1 — Random 1.19 (1.07–1.33) 0.002 —
HR, hazard ratio; CI, confidence interval; OS, overall survival; RT, radiation therapy; LC, local control; SBRT, stereotactic body radiotherapy; CRT, conventional radiotherapy.
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The number of the studies, as well as the number of 
the patients, included in this meta-analysis is relatively small. 
Also, the data in some of the included studies were ana-
lyzed using univariate analysis. As a result, the nature of the 
observed association is obscure. Another fact is that most of 
the data were derived from patients with stage I NSCLC. As 
a result, whether the observed association could be extrapo-
lated to patients with more advanced NSCLC is not certain. 
Therefore, more high-quality studies with sufficient informa-
tion needs to be performed, and it should lead to a more sig-
nificant meta-analysis.
In summary, the current meta-analysis confirmed an 
association of high pre-RT and post-RT SUV
max
 of primary 
tumor with poor outcome in NSCLC patients receiving RT. 
Such an association seems to be particularly strong for patients 
with stage I NSCLC receiving SBRT. And it supports further 
and high-quality investigations of SUV
max
 on 18F-FDG PET/CT 
for predicting poor outcome in NSCLC patients receiving RT.
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